Cynata Therapeutics (ASX: CYP) has executed a term sheet with FUJIFILM Corporation of Japan for the development and commercialisation of certain Cynata technology, including Cynata’s lead product, CYP-001. CYP-001 is an induced pluripotent stem cell (iPSC) derived mesenchymal stem cell (MSC) product that is anticipated to be the first allogeneic iPSC product to enter a clinical trial.
Are You Attending the Axiogenesis iPSC Applications Workshop on September 7-9, 2016?
Recently, Axiogenesis hosted an American symposium titled, “iPSC Derived Cells & Assays Come of Age.” Held on June 13, 2016, in Boston, Massachusetts, the symposium explored the topic of establishing global standards for iPSC-derived cell products. Because the conversation is critical to a wide range of stem cell industry stakeholders, it was widely attended by representatives from across the pharmaceutical, biotechnology, and chemical sectors.
To further support this dialog within the global marketplace, Axiogenesis is hosting Human iPSC Applications Workshop in Cologne, Germany on September 7 – 9, 2016. It will be the fourth year that Axiogenesis has organized a workshop at its headquarters in Cologne. [Read more…]
Infographic Highlights Preclinical Applications of iPSC-Derived Cells
Founded in 2001 and headquartered in Cologne, Germany, Axiogenesis is one of a small number of companies specializing in induced pluripotent stem cell (iPSC) products. The company also has an American subsidiary that was founded in 2014 and is located in Philadelphia, Pennsylvania. Since its launch, the company has grown into a market leader for in vitro models of healthy and diseased cell types and tissue. [Read more…]
Cynata Files to Begin Phase 1 Trial for CYP-001, World’s First Allogeneic iPSC Product
Australian stem cell company Cynata Therapeutics announced that it has filed an application to the UK Medicines and Healthcare products Regulatory Agency (MHRA) to commence a Phase I clinical trial for its lead product, CYP-001. CYP-001 is an iPSC-derived mesenchymal stem cell product that is anticipated to be the world’s first allogeneic iPSC product to enter a clinical trial.
To learn more, read the full press release issued by Cynata Therapeutics, printed with permission from Cynata CEO, Dr. Macdonald. [Read more…]
Join Axiogenesis for Human iPSC Application Workshop in Cologne (September 7 – 9, 2016)
Recently, Axiogenesis hosted an American symposium titled, “iPSC Derived Cells & Assays Come of Age.” Held on June 13, 2016, in Boston, Massachusetts, the symposium explored the topic of establishing global standards for iPSC-derived cell products. Because the conversation is critical to a wide range of stem cell industry stakeholders, the symposium was well-attended by representatives from across the pharmaceutical, biotechnology, and chemical sectors. Attendees also viewed case studies of iPS cells in drug development decision-making and biomedical research.
To further support this dialog within the global marketplace, Axiogenesis is now hosting Human iPSC Applications Workshop in Cologne, Germany on September 7 – 9, 2016. [Read more…]
- « Previous Page
- 1
- …
- 65
- 66
- 67
- 68
- 69
- …
- 79
- Next Page »